Get the Stockscreener App
138.79
1.82%
-2.57
After Hours:
138.79
Charles River Laboratories International Inc stock is traded at $138.79, with a volume of 920.26K.
It is down -1.82% in the last 24 hours and down -0.20% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$141.36
Open:
$141.205
24h Volume:
920.26K
Relative Volume:
0.55
Market Cap:
$5.82B
Revenue:
$4.06B
Net Income/Loss:
$413.08M
P/E Ratio:
17.33
EPS:
8.01
Net Cash Flow:
$560.48M
1W Performance:
+17.16%
1M Performance:
-0.20%
6M Performance:
-35.56%
1Y Performance:
-39.68%
1-Day Range:
$138.46
$143.46
1-Week Range:
$113.89
$144.77
52-Week Range:
$91.86
$254.15
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
138.79 | 5.82B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Charles River extends gains as Evercore upgrades after Q1 beat - MSN
Charles river raises 2025 guidance with focus on NAMs and cost optimization - MSN
Charles River surges after Q1 beat, guidance raise - MSN
Deutsche Bank lifts Charles River Labs target to $180 By Investing.com - Investing.com South Africa
Evercore ISI lifts Charles River Labs stock rating to Outperform By Investing.com - Investing.com Canada
Charles River Labs Stock Soars On Strategic Review Plan With Elliott: Retail Investors Optimistic - MSN
What 10 Analyst Ratings Have To Say About Charles River - Benzinga
Charles River stock upgraded at Evercore ISI (CRL:NYSE) - Seeking Alpha
Charles River (CRL) Stock Target Price Raised by Barclays Analyst | CRL Stock News - GuruFocus
Charles River (CRL) Target Price Raised by Baird Analyst | CRL Stock News - GuruFocus
Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2025 Earnings Call Transcript - Insider Monkey
Jefferies Adjusts Price Target on Charles River Laboratories International to $142 From $100, Maintains Hold Rating - marketscreener.com
What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing? - Yahoo Finance
Charles River (CRL) Sees Price Target Boost After Positive Q1 Insights | CRL Stock News - GuruFocus
Charles River (CRL) Receives Boost After Q1 Success | CRL Stock News - GuruFocus
Charles River Laboratories International Inc (CRL) Q1 2025 Earnings Call Highlights: Navigating ... - Yahoo
Evercore ISI lifts Charles River Labs stock rating to Outperform - Investing.com Australia
Charles River Laboratories Reports Q1 2025 Results - TipRanks
Decoding Charles River Laboratories International Inc (CRL): A S - GuruFocus
Charles River Labs Stock Soars On Strategic Review Plan With Elliott: Retail Investors Optimistic By Stocktwits - Investing.com India
Charles River announces strategic review including 'examination of various alternatives' - MSN
Charles River Labs reshapes board, plans strategic review By Investing.com - Investing.com Canada
Charles River Labs Q1 2025 slides: Beats expectations, raises guidance amid NAMs transition - Investing.com Canada
Charles River (CRL) Stock Upgraded Following Strong Q1 Results | - GuruFocus
Charles River (CRL) Stock Upgraded Following Strong Q1 Results | CRL Stock News - GuruFocus
Charles River Laboratories International Q1 2025 Earnings Call Transcript - MarketBeat
Charles River: Q1 Earnings Snapshot - Midland Daily News
Health Care Stocks Climb As Companies Show Strong Gains - Finimize
Charles River to initiate a review amid Elliott stakeIs a sale next? - Investing.com Canada
Charles River agrees with Elliott to add new directors, review business - Reuters
Charles River Laboratories (CRL) Adjusts 2025 Guidance Amid Revenue Decline - GuruFocus
Why Are Charles River Laboratories (CRL) Shares Soaring Today - Yahoo Finance
Charles River Labs agrees to strategic review, board shakeup amid activist pressure - The Business Journals
Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization - Benzinga
Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More - MSN
Earnings call transcript: Charles River Labs beats Q1 2025 earnings expectations - Investing.com
Charles River Laboratories (CRL) Shares Surge Following Strategic Review Announcement - GuruFocus
Charles River Labs Stock Soars as Firm Shakes Up Board, Launches Review - Yahoo Finance
Charles River Laboratories (CRL) Surges on Strong Q1 Results and Upgraded Outlook - GuruFocus
Charles River to Conduct Strategic Review, Signs Cooperation Deal With Elliott Investment Management - marketscreener.com
CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up - TradingView
Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Charles River stock surges after Q1 beat (CRL:NYSE) - Seeking Alpha
Charles River Laboratories International to Initiate Comprehensive Review of its Business to Enhance Long-Term Stockholder Value - marketscreener.com
Charles River Boosts FY25 Outlook; Stock Up 22% On Strategic Review AnnouncementUpdate - Nasdaq
Charles River Labs: Balancing Strong Q1 Performance with Market Uncertainties – Hold Rating Maintained - TipRanks
Charles River Laboratories Q1 Non-GAAP Earnings Rise, Revenue Falls - marketscreener.com
Charles River Laboratories’s (NYSE:CRL) Q1: Strong Sales, Stock Jumps 22.4% - Yahoo Finance
Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Charles River Laboratories Announces First-Quarter 2025 Results - BioSpace
CRL Revises FY Revenue Growth Forecast Following DSA Segment Improvement | CRL Stock News - GuruFocus
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):